The first tranche for Tracon Pharmaceuticals is $14m to fund the development of the antibody TRC105 through its phase two trials.

Third Rock led last year's $35m B round that also saw biotech company Genzyme's corporate venturing division join the investment consortium as a new investor and it remains on the company's share register, although not publicly mentioned in its latest $30m C round.

Sagent Pharmaceuticals sold 5.75 million shares at $16 each, compared to plans to price five million shares at between $14 and $16 per share.

The money will be drawn down in two tranches over the next two years to fund phase three development of Circassia's cat and ragweed allergy therapies.

In a regulatory filing first seen by Citybizlist, Valeritas has 20 investors in the round so far.

Nippon Life, Japan's largest private life assurer, now joins Munich Re, the world's largest reinsurer, as a minority owner of Best Doctors.

Private equity firm Symphony Technology Group has acquired a majority ownership interest in ImpactRx, leaving Merck Capital Ventures, the corporate venturing unit of US-based drugs group Merck, a shareholder.

Clal Biotechnology Industries, an Israel-based life sciences division of IDB Holding Corp and local drugs maker Teva Pharmaceutical Industries, is to start a NIS250m ($73m) fund for medical devices companies.

Alongside SR One backing F-star are Germany-based drugs maker Merck Serono's corporate venturing unit, MP Healthcare Venture, a jointly owned subsidiary of Mitsubishi Tanabe Pharma and its parent company Mitsubishi Chemical, and venture capital firms Atlas Venture, Aescap Venture, Novo Ventures and TVM Capital.